For research use only. Not for therapeutic Use.
Reversan (CBLC4H10) is a potent and nontoxic multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (Pgp) inhibitor[1][2].
| Catalog Number | R057347 |
| CAS Number | 313397-13-6 |
| Synonyms | N-(3-morpholin-4-ylpropyl)-5,7-diphenylpyrazolo[1,5-a]pyrimidine-3-carboxamide |
| Molecular Formula | C26H27N5O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H27N5O2/c32-26(27-12-7-13-30-14-16-33-17-15-30)22-19-28-31-24(21-10-5-2-6-11-21)18-23(29-25(22)31)20-8-3-1-4-9-20/h1-6,8-11,18-19H,7,12-17H2,(H,27,32) |
| InChIKey | JTRXWCLQFAZHGP-UHFFFAOYSA-N |
| SMILES | C1COCCN1CCCNC(=O)C2=C3N=C(C=C(N3N=C2)C4=CC=CC=C4)C5=CC=CC=C5 |
| Reference | [1]. Tivnan A, et al. Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme. Front Neurosci. 2015 Jun 16;9:218. [2]. Burkhart CA, et al. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 2009 Aug 15;69(16):6573-80. |
